Compare UEIC & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UEIC | RNTX |
|---|---|---|
| Founded | 1986 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.0M | 38.9M |
| IPO Year | 1993 | N/A |
| Metric | UEIC | RNTX |
|---|---|---|
| Price | $3.35 | $1.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $9.25 | ★ $10.00 |
| AVG Volume (30 Days) | 118.4K | ★ 212.7K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $390,997,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.35 | N/A |
| 52 Week Low | $2.69 | $1.04 |
| 52 Week High | $12.12 | $3.50 |
| Indicator | UEIC | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.06 | 52.79 |
| Support Level | $3.06 | $1.34 |
| Resistance Level | $3.36 | $1.58 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 85.38 | 57.14 |
Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.